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Aim: The aim was to describe the type and prevalence of potentially relevant drug- 
drug interactions (pDDIs) in a population of patients admitted for cardiovascular dis-
eases (CVD), and management strategies for reducing the occurrence of pDDIs.
Methods:	A	retrospective	cross-	sectional	study	was	performed	on	Cardiology	ward	of	
University	Clinical	Hospital	Center	 in	Belgrade,	Serbia.	A	total	of	527	patients,	with	
more than one prescription during hospital stay, were enrolled in this study. Data were 
obtained from medical records. LexiInteract was used as the screening tool.
Results:	At	 least	one	potentially	 relevant	pDDI	was	 identified	 in	83.9%	of	patients.	
Occurrence was significantly more prevalent in patients with higher number of drugs, 
multimorbidity, longer length of stay, arrhythmia, heart failure, infectious and respira-
tory	disease.	About	13%	of	pDDIs	exposures	were	accompanied	with	concurrent	renal	
or	liver	disease,	as	an	additional	risk	for	DDI	manifestation.	Among	CVD,	patients	with	
a history of myocardial infarction possessed the highest additional risk. The most com-
mon	potential	clinical	outcome	was	the	effect	on	cardiovascular	system	48.5%,	renal	
function	and/or	potassium	22.3%,	bleeding	9.5%,	impaired	glucose	control	6.8%	and	




blood pressure, electrolytes/potassium and blood glucose could have been employed 
in	monitoring	for	potential	consequence	of	72.2%	C	class	pDDIs.
Conclusions: Use of drug interaction screening tools can be beneficial risk mitigation 
strategy for potentially relevant pDDIs in CVD patients. DDI screening software could 
be linked to the patient’s laboratory results or clinical data regarding renal or liver 
function, as an approach to reinforce DDIs alert quality.
1  | INTRODUCTION
Cardiovascular diseases (CVD) have a significant share in the dis-
ease burden on societies worldwide.1 They are attributed a high 
morbidity and mortality rate, and significant economic burden 
derived from medical costs and working incapacity.2-4 Prescribed 
drugs significantly improve health and therapy outcomes, reduc-
ing the risk of future cardiovascular events. However, increasing 
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rate of multimorbidity and drug use leads to therapy becoming 
more complex and challenging.5 There is evidence of rising rates 
of negative outcomes through drug- related problems (DRPs) 
-	 drug-	drug	 interactions	 (DDIs)	 and	 adverse	 drug	 events	 (ADEs),	
in both outpatient and inpatient settings.6,7 DDI is defined as the 
alteration in a drug effect caused by concomitant administration 
of another drug. The mechanisms of DDIs could be broadly cat-
egorised as pharmacokinetic (drug concentration is altered on its 
site of action) and pharmacodynamic (the response is modified 
without changes in the pharmacokinetics of the affected drug).8 
The outcome can be harmful if the DDI causes an increase in the 
toxicity of the drug, but sometimes underexposure to the drug 
and decreased efficacy can be harmful as well.9	As	a	result,	DDIs	
are associated with increased length of stay and cost of hospi-
talisation.10,11 Other DDIs can be beneficial and valuable, such 
as the deliberate co- prescription of antihypertensive drugs and 
diuretics to achieve the optimal synergistic antihypertensive ef-
fect.9	One	 review	estimates	 that	DDIs	cause	17%	of	all	prevent-
able	ADEs	 in	hospitalised	patients	 and	 that	 approximately	1%	of	
patients	 will	 experience	 an	 ADE	 during	 hospitalisation	 due	 to	 a	
DDI.12 Meaningfully higher DDI rates were found in geriatrics set-
tings,	compared	to	internal	medicine,	both	in	the	USA	and	Europe.	





of two drugs known to interact, and a manifestation could occur 
in the exposed  patient.8,14 Due to patients variability, the epide-
miology data shows that the  prevalence of pDDIs is  consistently 
higher than that of actual DDIs.13 Contemporary standards for 
health systems  quality put the focus in research and clinical prac-
tice on recognising and implementing actions to prevent harm, 
that	 is,	 on	 preventable	 ADEs.15 Established strategy to minimise 
the risks associated with potentially harmful drug combinations is 
to reduce exposure to concurrent drug administration.16 Hence, 
pDDIs are identified as the predictable and preventable cause of 
ADEs	in	the	literature.17 Studies have found rates of pDDIs ranging 
from	about	15%	 to	66%	 in	hospital	 settings.12,18,19 Detailed data 
on pDDIs characteristics in patients admitted for CVD are lacking. 
One study investigated iatrogenic adverse events in the coronary 
care unit, assessing procedures, treatment, and diagnosis- related 
issues, in total.20 Other studies conducted on the cardiology ward, 
reported DDI and drug- food interactions frequency altogether or 
assessed only DDIs in the heart failure patients.21,22 The potential 
of using supporting electronic systems to manage pDDIs in CVD 
patients was not assessed. In this regard, the aim of the study was 
to describe the type and prevalence of potentially relevant pDDIs 
in CVD patients, and to assess the concurrent exposure to addi-
tional risk factors such as renal or liver disease, which may further 
affect drug exposure and therapy outcomes. In addition, manage-
ment strategies for reducing the occurrence of potentially relevant 
pDDIs were provided.
2  | METHODOLOGY
2.1 | Data collection and study setting
A	retrospective	observational	study	was	carried	out	on	Cardiology	
ward	 of	 University	 Clinical	 Hospital	 Center	 Bežanijska	 Kosa,	
Belgrade,	Serbia.	Medical	charts	were	obtained	for	a	total	of	651	
patients consecutively hospitalised in the period from June 2012 
to February 2013. Multiple patient’s admissions during the study 
period were excluded, keeping the data only for the first admis-
sion. Other inclusion criteria included hospital stay of at least 
24	hours	 and	 more	 than	 one	 prescription	 during	 the	 stay.	 The	
Ethics committee of the University Clinical Hospital Center ap-
proved this study. Data were obtained from paper medical charts 
and discharge letters, providing the information on patient’s so-
ciodemographic characteristics, medical history, the reason for 
hospitalisation and the therapy charts. Charlson comorbidity index 
was calculated for every patient through chart review version.23 
Screening for pDDIs was performed using LexiInteract database 
(Lexi- Comp, Inc., Hudson, Ohio).24 LexiInteract showed high sen-
sitivity	 (87%-	100%)	 and	 specificity	 (80%-	90%)	 according	 to	 the	
studies which have evaluated the performance of the DDI screen-
ing software.25-27	The	24	hour	interval	between	administrating	two	
drugs	was	used	 for	 assessing	pDDI	prevalence.	According	 to	 the	
LexiInteract	database	pDDIs	of	classes	A	(no	interaction)	and	B	(no	
action needed) are of academic, but not a relevant clinical concern. 
pDDIs	of	classes	X	(avoid	combination),	D	(consider	therapy	modi-
fication) and C (monitor therapy), are considered clinically relevant, 
What’s known
• There is evidence of rising rates of negative outcomes 
through drug-drug interactions (DDIs) and adverse drug 
events	(ADEs).





• Prevalence of potentially relevant pDDIs in inpatients 
with cardiovascular diseases was higher than expected 
(about	84%),	with	anticipated	clinical	outcome	on	the	car-
diovascular system, renal function and/or potassium, 
bleeding, glucose control and digoxin toxicity.
•	 About	13%	of	pDDIs	exposures	were	accompanied	with	
concurrent renal or liver disease, as an additional risk for 
DDI manifestation.
• Management strategies to avoid pDDIs or to monitor for 
potential consequences of pDDIs in patients with cardio-
vascular disease were proposed.
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as they require healthcare professionals attention and assessment 
of benefit/risk ratio for an individual patient. The pDDI character-
istics were extracted from the monograph, including information 
on reliability rating, which indicates the quantity and nature of doc-
umentation for interaction. In addition, the interacting monograph 
was used to define the potential clinical outcome and to make rec-
ommendations for improving management of the identified poten-
tially relevant pDDIs.
2.2 | Statistical analysis




attributed	a	 lower	 risk,	 compared	 to	X	and	D.	As	 this	class	 showed	
almost ubiquitous presence in our study, with many patients having 
several identified C interactions, the expected risk of potential clinical 
outcome	is	substantially	higher.	For	that	purpose,	the	occurrence	of	X,	
D, and more than two C pDDIs was considered as potentially relevant 
risk	(binary	code	1).	Nonparametric	tests	were	used	for	the	analysis.	
The crude prevalence ratio was calculated as the probability of pDDIs 
occurrence in the patients with a particular characteristic relative to 
the probability in patients without that characteristic. The association 
between patient characteristics and pDDIs occurrence was assessed 
by	 Chi-	square	 or	 Fisher’s	 exact	 test	 for	 independence.	 Wilcoxon	
signed-	rank	and	McNemar’s	test	were	used	to	evaluate	the	difference	
in the prevalence and the number of pDDIs after considering man-
agement recommendations. Continuous descriptive variables in the 
text and tables were expressed by mean ± SD, with range, whereas 
categorical data and prevalence were presented as number (percent-
age),	N	(%).	For	all	of	the	tests,	a	P < .05 was considered statistically 
significant.
3  | RESULTS
3.1 | Characteristics of the study population
A	total	of	527	patients	were	included	in	this	study.	The	study	popu-
lation	 consisted	 of	 slightly	more	males	 (55.4%),	 and	 about	 70%	 el-
derly	 (	≥	65	years).	The	mean	number	of	drugs	per	patient	was	7.7;	
moreover,	about	30%	of	patients	were	prescribed	10	or	more	drugs.	
Hypertension, arrhythmia and heart failure were the most prevalent 
diagnoses, and more than one forth of patients had diabetes mellitus. 
The most frequently prescribed drugs were affecting the cardiovascu-
lar	system	(53.8%),	blood	and	blood	forming	organs	(14.7%),	and	ali-
mentary	tract	and	metabolism	(14.3%).	Descriptive	demographic	and	
clinical data are presented in Table 1.
3.2 | Prevalence and characteristics of pDDIs
The	most	of	 the	 identified	pDDIs	were	of	moderate	severity	 (91%),	
whereas	 major	 were	 less	 represented	 (8.6%).	 Reliability	 rating	 was	
determined	as	good	in	57.8%	of	pDDIs,	followed	by	fair	34.3%,	excel-
lent	5.7%	and	poor	in	2.3%.	Pharmacodynamic	pDDIs	were	the	most	
common,	 with	 79.8%	 share,	 and	 pharmacokinetic	 and	 pharmacoki-
netic/pharmacodynamic	 were	 almost	 equally	 distributed	 (10.8	 and	
8.6%,	 respectively).	Metabolism	was	 involved	 in	 50.2%	 of	 pharma-
cokinetic	pDDIs,	renal	excretion	in	12.5%,	and	the	absorption	process	
in	3%.	Table	2	shows	the	main	drug	pairs	involved	in	identified	pDDIs.
TABLE  1 Patient’s demographic and clinical data
Characteristics
N (%, n = 527) or 

































Gastrointenstinal system disease 34	(6.5)
Liver disease 26	(4.9)
Infectious disease 23	(4.4)
Endocrine disease, excluding diabetes 21	(4)
Mental disease 14	(2.7)
Neurodegenerative	diseases 5	(0.9)
CCI, Charlson comorbidity index





than	40%	of	 patients	were	 exposed	 to	 two	 types	 of	 pDDIs,	mostly	
concurrent	 X	 and	 C	 exposure.	 Table	3	 shows	 calculated	 prevalence	
and crude prevalence ratios (PR) for potentially relevant pDDIs expo-
sure,	according	to	patients	demographic	and	clinical	characteristics.	X	
class was significantly more prevalent in patients with the number of 
drugs	7-	9	and	≥	10	(PR	3.07	and	8.13,	respectively),	with	arrhythmia	
(PR	4.27),	 infectious	 (PR	4.38)	 or	 respiratory	disease	 (PR	3.18).	The	
prevalence of exposure to D class was increased in patients with a 
longer length of stay (more than 7 days), a higher number of drugs, 
heart failure and a history of myocardial infarction. In heart failure and 
post- myocardial infarction patients, a significant difference (P < .05) in 
D prevalence was found between groups with and without polyphar-
macy, which means that number of drugs was the confounder. The 
number of drugs showed significant association with C class exposure, 
with	PR	 ranging	 from	5.76	 to	7.88	 in	 different	 strata.	Besides	 that,	
C class was more prevalent in elderly and patients with heart failure. 
Multimorbidity (Charlson comorbidity index > 3) was significantly as-
sociated	with	D	and	C	class	exposure,	resulting	 in	38%	and	22%	in-
crease in prevalence, respectively.
Renal	 and/or	 liver	 disease	was	 present	 in	 average	 12.9%	 of	 ex-
posures	to	potentially	relevant	pDDIs,	range	0	-	28.2%.	In	the	group	
of CVD, patients with the history of myocardial infarction possessed 
the highest additional risk. Impaired function of elimination organs, as 
an	independent	patient	risk	factor	for	ADEs,	may	further	affect	drug	
exposure and increase the possibility of potential clinical outcome; for 
example, statin toxicity.
The most common potential clinical outcome was cardiovascular 
48.5%,	 related	to	effects	on	heart	 rate,	 rhythm	or	blood	pressure.	
The second most common was the effect on renal function and/
or	potassium	22.3%,	 followed	by	bleeding	9.5%,	 impaired	glucose	





X amiodarone + ciprofloxacin 6 enhanced QTc- prolonging effect (highest 
and moderate risk agents 
coadministration)
PD
haloperidol + potassium chloride 4 enhanced ulcerogenic effect of potassium 
chloride (applies to its solid oral dosage 
forms)
PD
fenoterol/ipratropium + potassium 
chloride
3




fenoterol/ipratropium + carvedilol 3 diminished bronchodilatatory effect due to 
nonselective beta blockers
PD
D amiodarone + warfarin 37 increased serum concentration of vitamin 
K	antagonists	and	anticoagulant	effect	
PK 
metabolism	inhibition	via	CYP2C9amiodarone + acenocoumarol 25
potassium chloride + spironolactone 49 enhanced hyperkalemic effect of 
potassium- sparing diuretics
PD
diclofenac + furosemide 33 diminished diuretic effect of loop diuretics; 
enhanced	nephrotoxic	effect	of	NSAIDs
PD
clopidogrel + pantoprazol 26 decreased serum concentration of the 
active metabolite(s) of clopidogrel
PK 
metabolism	inhibition	via	CYP2C19
C hypotensive agents + hypotensive 
agents
2052 enhanced hypotensive and adverse/toxic 
effect of hypotensive agents
PD









anticoagulants + anticoagulants or 
antiplatelets
175 enhanced anticoagulant effect PD
hypoglycaemic agents + loop 
diuretics
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control	6.8%	and	digoxin	 toxicity	4.6%.	Figure	1	 shows	 frequency	
of potential clinical outcomes resulting from pDDIs, with relative 
contributions	 of	 X,	D,	 and	 C	 class	 on	 the	 right	 side,	 showing	 the	
possibility of applying different management strategies to reduce 
the occurrence of potential clinical outcomes. Category “Other” 
comprised clinical outcomes that could not be easily assigned to 
one	main	 category.	Anticholinergic,	 salmeterol-	related,	 and	 toxici-
ties	 emerging	 from	NSAIDs	 pharmacological	 duplication	were	 ex-
pected	 from	 the	 X	 interactions.	On	 the	 other	 hand,	 almost	 equal	
frequencies were expected for drug toxicity and decreased drug ef-
ficacy regarding D class. Increased exposure to methylprednisolone 
and selective serotonin reuptake inhibitors were expected, as well 
as	the	NSAIDs	duplication	consequences.	In	contrast,	pDDIs	at	the	
absorption level could lead to systemic underexposure to quinolone 
antibiotics and levothyroxine.
3.3 | Management strategies of potentially 
relevant pDDIs
LexiInteract monographs of C class state that the benefits of the con-
current use of two medications usually outweigh the risks, and rather 
an	appropriate	monitoring	plan	should	be	implemented.	As	previously	
discussed relevance for C pDDIs in the methodology section, man-
agement	strategies	to	avoid	pDDIs	 listed	 in	Table	4	were	applied	to	
C class as well, to calculate the total number of the relevant pDDIs 
that could have been potentially prevented by using a certain surveil-
lance	 system.	 Table	4	 summarizes	 recommendations	 for	 improving	
the management of the identified pDDIs, giving the assessment of the 
preventability of potentially relevant pDDIs. Management strategies 
were	 categorised	 in	 14	 recommendations,	 based	 on	 drug	 pharma-
cokinetic or pharmacodynamic properties, or were related to the drug 
administration	 process.	 Recommendations	 to	 avoid	X	 and	D	occur-
rence	in	81%	of	pDDIs	included:	using	paracetamol	instead	of	NSAID	
or	alternative	NSAID	(38%),	alternative	antibiotic	or	antifungal,	mostly	
regarding	QTc-	prolonging	potential	 (20.4%),	H2 receptor antagonist 
instead	of	PPI	(8.3%),	avoiding	therapeutic	duplication	(7.3%),	and	al-
ternative	HMG-	CoA	reductase	inhibitor	(7%).	Most	of	the	suggestions	
for management of C class referred to closely patient monitoring of 
hemodynamic status or laboratory results: heart rate, blood pressure, 
electrolytes/potassium and blood glucose. These clinical or laboratory 
parameters could have been employed in monitoring for potential 
consequence	of	72.2%	C	class	pDDIs.
4  | DISCUSSION
DDIs are the most frequently detected DRPs in hospitalised pa-
tients.28,29	None	of	the	drug	interactions	screening	tools	is	currently	
incorporated in secondary or tertiary institutions of the Serbian health 
system. This is the first study conducted to assess the prevalence 
and characteristics of pDDIs in a population of inpatients admitted 
for CVD. The study revealed the high total prevalence of pDDIs of 
94.7%,	which	 is	 somewhat	higher	compared	 to	 inpatient	settings	 in	
other	countries	(19.3%-	87.2%).5,10,18,28,30-32 The main reason for ob-
served discrepancies in results was probably the use of different DDI 
data bases, differences in prescribing patterns between countries and 
patient population included in this study.
The number of drugs prescribed was among the characteristics 
most	strongly	associated	with	 the	occurrence	of	pDDIs	and	ADRs	 in	
many studies.7,22,31,33 In our study PR for exposure to potentially rele-
vant pDDIs in patients with higher number of drugs ranged from 3.07 
up to 25.20, compared to 1- 3 drugs as a reference category. The high-
est PR values were calculated for D class exposure. In line with these 
findings, the prevalence of potentially relevant pDDIs in patients with 
a specific clinical characteristic were further tested regarding present 
polypharmacy.	X	class	was	significantly	more	prevalent	in	patients	with	
arrhythmia, infectious and respiratory disease, irrespective of number of 
drugs, which gives important and precise directions for future research 
in CVD therapy outcomes. Furthermore, exposure to D and more than 
two C class pDDIs were more common in patients with heart failure 
and multimorbidity, although D occurrence in heart failure patients was 
associated with polypharmacy. These results are consistent with the 
prior	research,	as	ACE	inhibitors,	digoxin,	furosemide	and	spironolac-
tone	were	broadly	identified	as	predictors	for	DDIs	and	ADRs.31,32,34-36 
These commonly used drugs for heart failure are usually prescribed in 
combinations, thus increasing the number of drugs in therapy. Findings 
on the co- therapy involved in pDDIs, such as ciprofloxacin, macro-
lide antibiotics, and beta- agonists, are in close agreement with other 
F IGURE  1 Frequency of potential 
clinical outcomes resulting from pDDIs 
(left)	with	relative	contributions	of	X,	D	and	
C class (right)
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studies.32,34 Results regarding the association of age with pDDIs are 
inconsistent. Some studies showed higher odds of exposure to a pDDI 
in older patients,10,31 but the association did not remain significant after 
adjusting for polypharmacy and other factors.7,10
Medicines used in CVD, antiinfectives, anticancer, antidiabetics 
and anti- inflammatory/analgesics were identified as the main classes 
involved	 in	 hospitalisation	 resulting	 from	ADRs,	ADEs,	 and	DRPs.37 
Also,	 Dequito	 et	al	 found	 that	 drugs	 for	 blood	 and	 blood	 forming	
organs and cardiovascular drugs were more frequently prescribed in 
patients	with	actual	ADRs,	than	with	potential	ADEs.29 It could be con-
cluded	that	these	drugs	rather	led	to	the	manifestation	of	ADEs	in	the	
studied population. Therefore, the likelihood for pDDIs manifestation 
is our study population is increased, because of the fairly prescription 
of these drugs. Potential clinical outcomes on cardiovascular system, 
renal function and/or potassium level, bleeding and digoxin toxicity 
were dominantly expected in our study.
Some studies estimated that only relatively small number of 
all	 identified	 pDDIs	 resulted	 in	 an	 adverse	 event	 (0.1%-	5.6%),12,32 
whereas	others	revealed	that	22%-	26%	of	ADEs	prompting	hospital-
isation were due to DDIs.38 Our study population consisted mostly 
of elderly patients, which are more susceptible to DDIs, due to age- 
related alterations in pharmacokinetics and pharmacodynamics.39 
The study unveiled notable proportion of potentially relevant pDDIs 
exposures with concurrent presence of renal and/or liver disease. In 
addition,	some	authors	noted	that	CVD	increased	ADEs	risk,	through	
heart failure influence on drug elimination by altering renal and he-
patic perfusion.40 It is also stated that the prevalence of actual DDIs 
could	be	underestimated	since	the	link	between	ADEs	and	underlying	
DDI was probably under- recognised as symptoms frequently may be 
attributed to underlying diseases.18
Based	on	the	LexiInteract	monographs	data,	14	different	man-
agement recommendations were proposed in our study, which 
TABLE  4 Management recommendations and the assessment of the potentially relevant pDDIs preventability
No. of pDDIs





Cardioselective beta blocker 5 8 71
Alternative	HMG-	CoA	reductase	inhibitor 22 6
Alternative	antibiotic/antifungal 12 52 74
Alternative	PPI 6 56
H2 receptor antagonist instead of PPI 26 32
PPI instead of H2 receptor antagonist 51
Paracetamol	instead	of	NSAIDs/alternative	NSAID 86/33 280




Changes in the route of administration 12 1
Drug administration with an acidic beverage 1
Separate dosing time 4 12
Flushing infusion lines between administrations 3
Monitoring
Electrolytes and heart rate 1920




Initial	number	of	pDDIs,	N 42 494 5055
Revised	number	of	pDDIs,	N 10* 213* 4394*
Initial	prevalence	of	pDDIs,	No.	of	patients	(%) 30 (5.7) 250	(47.4) 494	(93.7) 428	(81.2)
Revised	prevalence	of	pDDIs,	No.	of	patients	(%) 8	(1.5)* 165	(31.3)* 491	(93.2) 416	(78.9)*
abased on pharmacokinetic properties
*McNemar’s	or	Wilcoxon	signed-	rank	test	significant	at	P < .001
ACE,	 angiotensin	 converting	 enzyme;	 AT2,	 angiotensin	 II	 receptor	 type	 2;	 HMG-	CoA	 -	 3-	hydroxy-	3-	methyl-	glutaryl-	coenzyme	 A;	 H2, histamine H2- 
receptor;	NSAID,	non-	steroidal	anti-	inflammatory	drug;	PPI, proton pump inhibitor
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were based on the pharmacokinetic or pharmacodynamic drug 
characteristics or were realted to the drug administration process. 
The preventability rate was assessed for identified pDDIs to evalu-
ate the possibility of using electronic systems as the risk mitigation 
strategy.	Regarding	the	management	of	X	and	D	pDDIs	which	are	
assigned a high risk and require therapy modifications, five rec-
ommendations	advised	in	total	of	81%	of	cases	were:	using	parac-
etamol	 instead	of	NSAID	or	alternative	NSAID	 (38%),	 alternative	
antibiotic	 or	 antifungal	 (20.4%),	 H2 receptor antagonist instead 
of	 PPI	 (8.3%),	 avoiding	 therapeutic	 duplication	 (7.3%),	 and	 alter-
native	HMG-	CoA	 reductase	 inhibitor	 (7%).	Recommendations	 re-
garding monitoring for potential consequences of pDDIs included: 
electrolytes	 and	 heart	 rate	 (in	 1920	 pDDIs),	 blood	 pressure	 and	
heart	rate	(1000),	electrolytes/potassium	(472)	and	blood	glucose	
(259),	which	could	be	frequently	and	feasibly	assessed	during	the	
hospital stay. Healthcare professionals are encouraged to seek to 
identify DRPs, using data bases and software to screen for pDDIs. 
There is rising evidence that clinical- pharmacist interventions, 
alone or combined with the electronic alerting system, may reduce 
clinically significant DDIs.41,42 Extra caution is needed in patients 
with decreased renal or liver function, in which a higher risk of 
adverse clinical outcome could be expected. DDI screening elec-
tronic system should be linked to CVD patients laboratory results, 
especially potassium and glucose. In addition, drug pharmacoki-
netic properties regarding the dominant way of elimination should 
be considered in pDDIs alerting systems, and linked to the data on 
patients’ renal or liver function, as these patients intrinsic charac-
teristics could further influence the risk/benefit ratio of concom-
itant drug use.
Due to the retrospective design, our study has several limitations. 
It was performed as the cross- sectional study, obtaining the data on 
the total therapy used during the hospital stay. The temporal associa-
tion or timing of drug introduction and potential clinical outcome is not 
known. For a better understanding of the DDI impact on CVD therapy 
outcomes	 and	 burden,	 a	 prospective	 design	would	 be	 necessary.	A	
close follow- up after discharge with more detailed patient information 
and	 laboratory	parameters	 is	 required.	A	multi-	centred	 study	would	
diminish possible differences in prescribing patterns and would ascer-
tain better generalisability of the data. Other limitations are closely 
related to the drug interaction screening software, as it checks each 
drug pair for pDDI and the influence of an additional drug to the DDI 
manifestation and consequence is not considered. The common po-
tential clinical outcome expected from pDDIs in our study involves 
cardiovascular system, which could imply more difficult detection of 
DDIs in patients with CVD in future research, as the DDI manifesta-
tion may be attributed to CVD.
5  | CONCLUSION
This study has revealed the high prevalence of potentially rel-
evant pDDIs in inpatients admitted for CVD. The exposure was 
significantly increased in patients with higher number of drugs, 
multimorbidity, and longer length of stay. The presence of arrhyth-
mia and heart failure, as well as infectious and respiratory disease, 
was associated with increased prevalence of pDDIs. In average, 
about	 13%	 of	 pDDIs	 exposures	 were	 accompanied	 with	 concur-
rent renal or liver disease, as an additional risk for DDI manifesta-
tion. The most common potential clinical outcome was the effect 
on	cardiovascular	system	48.5%,	the	effect	on	renal	function	and/
or	potassium	22.3%,	followed	by	bleeding	9.5%,	 impaired	glucose	
control	 6.8%	 and	 digoxin	 toxicity	 4.6%.	 Use	 of	 drug	 interaction	
screening tools can be beneficial risk mitigation strategy for po-
tentially relevant pDDIs in CVD patients. DDI screening software 
could be linked to patients’ laboratory results or clinical data re-
garding renal or liver function, as an approach to reinforce DDIs 
clinical significance and alert quality.
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